20:24 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

Omeros Corp. (NASDAQ:OMER) reported data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721 for 12 weeks led to a 0.4% greater reduction in median proteinuria...
19:53 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Delta-Fly raises ¥3.3B in IPO

Cancer company Delta-Fly Pharma Inc. (Tokyo:4598) raised ¥3.3 billion ($29.3 million) in IPO on Oct. 3 through the sale of 700,000 shares at ¥4,770. The price values the company at ¥20.5 billion ($180.1 million). Delta-Fly had...
23:38 , Oct 2, 2018 |  BC Extra  |  Clinical News

Omeros' OMS721 underwhelms in Phase II

Shares of Omeros Corp. (NASDAQ:OMER) regained some ground Tuesday a day after the stock tumbled on data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721...
22:23 , Sep 21, 2018 |  BioCentury  |  Finance

Flying Delta in Japan

That Delta-Fly Pharma Inc. is slated to become only the third biotech to go public on Tokyo Stock Exchange’s Mothers in three years is the latest reminder that tough listing standards are still making it...
16:15 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

J&J planning submission for Invokana in CKD following Phase III readout

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
22:10 , Jul 16, 2018 |  BC Extra  |  Clinical News

J&J planning submission for Invokana in CKD

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat patients...
23:29 , Apr 13, 2018 |  BioCentury  |  Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
19:15 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

AZ, Acerta report additional Phase II data for Calquence in MCL

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) reported additional data from the Phase II ACE-LY-004 trial in 124 patients with relapsed or refractory mantle cell lymphoma (MCL) showing that Calquence acalabrutinib...
05:39 , Jan 19, 2018 |  BC Week In Review  |  Financial News

Pherecydes raises €8.7M series B

Anti-infectives company Pherecydes Pharma S.A. (Romainville, France) raised €8.7 million ($10.6 million) in a series B round led by new investor GO Capital on Jan. 16. New investors Omnes Capital and Fa Dièse and other...